Abraham, Jean E.

Multi-omic machine learning predictor of breast cancer therapy response

Sammut, S.-J., Crispin-Ortuzar, M., Chin, S.-F., Provenzano, E., Bardwell, H. A., Ma, W., Cope, W., Dariush, A., Dawson, S.-J., Abraham, J. E., et al. (2022) · Nature

Breast Cancer Treatment StudiesCancer Genomics and Diagnostics

Cited by 654

Comparison of tumor-informed and tumor-naïve sequencing assays for ctDNA detection in breast cancer

Santonja, A., Cooper, W. N., Eldridge, M. D., Edwards, P. A. W., Morris, J. A., Edwards, A. R., Zhao, H., Heider, K., Couturier, D., Vijayaraghavan, A., et al. (2023) · EMBO Molecular Medicine

Cancer Genomics and DiagnosticsBRCA gene mutations in cancer

Cited by 66

Body mass index and breast cancer survival: a Mendelian randomization analysis

Guo, Q., Burgess, S., Turman, C., Bolla, M. K., Wang, Q., Lush, M., Abraham, J., Aittomäki, K., Andrulis, I. L., Apicella, C., et al. (2017) · International Journal of Epidemiology

Cancer Risks and FactorsGenetic Associations and Epidemiology

Cited by 64

The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer

Abraham, J. E., Pinilla, K., Dayimu, A., Grybowicz, L., Demiris, N., Harvey, C., Drewett, L. M., Lucey, R., Fulton, A., Roberts, A. N., et al. (2024) · Nature

PARP inhibition in cancer therapyBreast Cancer Treatment Studies

Cited by 53

PARTNER: A randomized, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in patients with triple-negative and/or germline BRCA-mutated breast cancer.

Drewett, L., Lucey, R., Pinilla, K. A., Grybowicz, L., Wulff, J., Dayimu, A., Demiris, N., Vallier, A.-L., Qian, W., Machin, A., et al. (2022) · Journal of Clinical Oncology

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 6